tumor metabolism and prostate cancer therapy

2005.09-2011.06: Graduate student (PhD), Shanghai Institute of Biochemistry and Cell Biology, CAS

2001-2005: Undergraduate student, Life Science department, Fudan University

1. Zejie Mei^#, Tao Yang^#, Ying Liu, Yuanyuan Gao, Zemin Hou, Qian Zhuang, Dongyin He, Xuebin Zhang, Qilong Tan, Xuyou Zhu, Yingyi Qin, Xi Chen, Chengdang Xu, Cuidong Bian, Xinan Wang, Chenyang Wang, Denglong Wu, Shengsong Huang*, Zhenfei Li*. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Reports Medicine. 2022 May 17; 3 (5):100608. DOI: 10.1016/j.xcrm.2022.10060.
2. Zemin Hou^#, Shengsong Huang^#, Zejie Mei^#, Longlong Chen^#, Jiacheng Guo, Yuanyuan Gao, Qian Zhuang, Xuebin Zhang, Qilong Tan, Tao Yang, Ying Liu, Yongnan Chi, Lifengrong Qi, Ting Jiang, Xuefeng Shao, Yan Wu, Xiaojun Xu, Jun Qin, Ruobing Ren, Huiru Tang* Denglong Wu*, Zhenfei Li*. Inhibiting 3bHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Reports Medicine. 2022 Mar 15;3(3):100561. doi: 10.1016/j.xcrm.2022.100561.
3. Zhenfei Li, Mohammad Alyammani, Jianneng Li, Kevin Rogacki, Mohamed Abazeed, Sunil Upadhyay, Steven P. Balk, Mary-Ellen Taplin, Richard J. Auchus, Nima Sharifi. Redirecting abiraterone metabolism to biochemically fine tune prostate cancer therapy. Nature. 533, 547-551 (2016).
4. Mohammad Alyamani, Zhenfei Li, Sunil K Upadhyay, David J Anderson, Richard J Auchus, Nima Sharifi. Development and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. J Steroid Biochem Mol Biol, doi: 10.1016. (2016).
5. Zhenfei Li, Andrew Bishop, Mohammad Alyamani, Jorge A. Garcia, Robert Dreicer, Dustin Bunch, Jiayan Liu, Sunil K. Upadhyay, Richard J. Auchus, Nima Sharifi. Conversion of abiraterone to D4A drives antitumor activity in prostate cancer.Nature. 523, 347-351 (2015).
6. Hamid Emamekhoo, Zhenfei Li and Nima Sharifi. Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell cycle. 14, 3213-3214 (2015).
7. Cong Fei, Zhenfei Li, Chen Li, Yuelei Chen, Zhangcheng Chen, Xiaoli He, Li Mao, XinWang, Rong Zeng and Lin Li. Smurf1-mediated Lys29-linked nonproteolytic polyubiquitination of axin negatively regulates Wnt/beta-catenin signaling. Mol Cell Biol. 33, 4095-105 (2013).
8. Zhenfei Li*, Fen Nie*, Sheng Wang, Lin Li. Histone 4 Lys-20 Mono-Methylation by SET8 Mediates Wnt Target Gene Activation.Proc Natl Acad Sci USA. 108, 3116-23 (2011). (*co-first author)
9. Zhihui Xie*, Yongfeng Chen*, Zhenfei Li, Ge Bai, Yue Zhu, Ye-Guang Chen, Francois Guillemot, Lin Li, Naihe Jing. Smad6 Inhibits Wnt/β-catenin Pathway by Recruiting CtBP to Promote Neuronal Differentiation. Proc Natl Acad Sci USA. 108, 12119-24 (2011). (*co-first author)
10. Meng Li, He Wang, Tao Huang, Jiyong Wang, Yu Ding, Zhenfei Li, Jinkuo Zhang and Lin Li. TAB2 scaffolds TAK1 and NLK in repressing canonical Wnt signaling. J Biol Chem. 285, 13397-13404 (2010).

Mechanisms underlying tumor metabolism and its clinical implication.

2015 Prostate Cancer Foundation Young Investigator Award